Liver Transplantation and Uveal Malignant Melanoma

University of Oslo (UIO)

Status: Completed

Conditions: Uveal Malignant Melanoma

Treatments: Procedure: Liver transplantation

Study type: Interventional

Funder types: Other

Identifiers

NCT01311466

S-06408

Details and patient eligibility

About

Patients with uveal malignant melanoma with liver metastases have median survival of less than 12 months. There is no established treatment showing increased overall survival. The study will determine if liver transplantation will result in long term survival in patients with liver metastases from uveal malignant melanoma.

Enrollment: 2 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Uveal malignant melanoma
• Liver metastases
• ECOG 0-1

Exclusion criteria

• Extra hepatic disease
• Previous other malignancy
• Previous organ transplantation

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

2 participants in 1 patient group

Liver transplantation

Experimental group

Description:

The liver transplantation will be performed as described by the standard protocol, Liver Transplantation Protocol (Version 2006) at the Oslo University Hospital

Treatment:

Procedure: Liver transplantation